123 related articles for article (PubMed ID: 26564000)
1. TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma.
Bagratuni T; Terpos E; Eleutherakis-Papaiakovou E; Kalapanida D; Gavriatopoulou M; Migkou M; Liacos CI; Tasidou A; Matsouka C; Mparmparousi D; Dimopoulos MA; Kastritis E
Br J Haematol; 2016 Jan; 172(1):44-7. PubMed ID: 26564000
[TBL] [Abstract][Full Text] [Related]
2. Association of TLR4 (D299G, T399I), TLR9 -1486T>C, TIRAP S180L and TNF-α promoter (-1031, -863, -857) polymorphisms with risk for systemic lupus erythematosus among South Indians.
Rupasree Y; Naushad SM; Rajasekhar L; Uma A; Kutala VK
Lupus; 2015 Jan; 24(1):50-7. PubMed ID: 25182168
[TBL] [Abstract][Full Text] [Related]
3. Common variants of genes encoding TLR4 and TLR4 pathway members TIRAP and IRAK1 are effective on MCP1, IL6, IL1β, and TNFα levels in type 2 diabetes and insulin resistance.
Degirmenci I; Ozbayer C; Kebapci MN; Kurt H; Colak E; Gunes HV
Inflamm Res; 2019 Sep; 68(9):801-814. PubMed ID: 31222667
[TBL] [Abstract][Full Text] [Related]
4. Polymorphism of IL-10 receptor β affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib.
Kasamatsu T; Saitoh T; Ino R; Gotoh N; Mitsui T; Shimizu H; Matsumoto M; Sawamura M; Yokohama A; Handa H; Tsukamoto N; Murakami H
Hematol Oncol; 2017 Dec; 35(4):711-718. PubMed ID: 27405747
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphisms in the Toll-like receptor signalling pathway in Helicobacter pylori infection and related gastric cancer.
Castaño-Rodríguez N; Kaakoush NO; Pardo AL; Goh KL; Fock KM; Mitchell HM
Hum Immunol; 2014 Aug; 75(8):808-15. PubMed ID: 24929142
[TBL] [Abstract][Full Text] [Related]
7. TIRAP Ser180Leu polymorphism is associated with Behcet's disease.
Durrani O; Banahan K; Sheedy FJ; McBride L; Ben-Chetrit E; Greiner K; Vaughan RW; Kondeatis E; Hamburger J; Fortune F; Stanford MR; Murray PI; O'Neill LA; Wallace GR
Rheumatology (Oxford); 2011 Oct; 50(10):1760-5. PubMed ID: 21705416
[TBL] [Abstract][Full Text] [Related]
8. Influence of genetic variations in TLR4 and TIRAP/Mal on the course of sepsis and pneumonia and cytokine release: an observational study in three cohorts.
Kumpf O; Giamarellos-Bourboulis EJ; Koch A; Hamann L; Mouktaroudi M; Oh DY; Latz E; Lorenz E; Schwartz DA; Ferwerda B; Routsi C; Skalioti C; Kullberg BJ; van der Meer JW; Schlag PM; Netea MG; Zacharowski K; Schumann RR
Crit Care; 2010; 14(3):R103. PubMed ID: 20525286
[TBL] [Abstract][Full Text] [Related]
9. CTLA-4 polymorphisms are associated with treatment outcomes of patients with multiple myeloma receiving bortezomib-based regimens.
Qin XY; Lu J; Li GX; Wen L; Liu Y; Xu LP; Chang YJ; Liu KY; Jiang ZF; Huang XJ
Ann Hematol; 2018 Mar; 97(3):485-495. PubMed ID: 29264740
[TBL] [Abstract][Full Text] [Related]
10. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.
Dimopoulos MA; Kastritis E; Christoulas D; Migkou M; Gavriatopoulou M; Gkotzamanidou M; Iakovaki M; Matsouka C; Mparmparoussi D; Roussou M; Efstathiou E; Terpos E
Leukemia; 2010 Oct; 24(10):1769-78. PubMed ID: 20739955
[TBL] [Abstract][Full Text] [Related]
11. Association of TIRAP (MAL) gene polymorhisms with susceptibility to tuberculosis in a Chinese population.
Zhang YX; Xue Y; Liu JY; Zhao MY; Li FJ; Zhou JM; Wang HJ; Li JC
Genet Mol Res; 2011 Jan; 10(1):7-15. PubMed ID: 21218381
[TBL] [Abstract][Full Text] [Related]
12. Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib.
Vangsted AJ; Klausen TW; Abildgaard N; Andersen NF; Gimsing P; Gregersen H; Nexø BA; Vogel U
Ann Hematol; 2011 Oct; 90(10):1173-81. PubMed ID: 21347685
[TBL] [Abstract][Full Text] [Related]
13. Association of interacting genes in the toll-like receptor signaling pathway and the antibody response to pertussis vaccination.
Kimman TG; Banus S; Reijmerink N; Reimerink J; Stelma FF; Koppelman GH; Thijs C; Postma DS; Kerkhof M
PLoS One; 2008; 3(11):e3665. PubMed ID: 18987746
[TBL] [Abstract][Full Text] [Related]
14. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.
Dimopoulos MA; Roussou M; Gkotzamanidou M; Nikitas N; Psimenou E; Mparmparoussi D; Matsouka C; Spyropoulou-Vlachou M; Terpos E; Kastritis E
Leukemia; 2013 Feb; 27(2):423-9. PubMed ID: 22763386
[TBL] [Abstract][Full Text] [Related]
15. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
Griffin PT; Ho VQ; Fulp W; Nishihori T; Shain KH; Alsina M; Baz RC
Cancer; 2015 Oct; 121(20):3622-30. PubMed ID: 26149422
[TBL] [Abstract][Full Text] [Related]
16. LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens.
Chim CS; Sim J; Tam S; Tse E; Lie AK; Kwong YL
Eur J Haematol; 2015 Apr; 94(4):330-5. PubMed ID: 25135740
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
Broyl A; Corthals SL; Jongen JL; van der Holt B; Kuiper R; de Knegt Y; van Duin M; el Jarari L; Bertsch U; Lokhorst HM; Durie BG; Goldschmidt H; Sonneveld P
Lancet Oncol; 2010 Nov; 11(11):1057-65. PubMed ID: 20864405
[TBL] [Abstract][Full Text] [Related]
18. Genetic Variation in Pattern Recognition Receptors and Adaptor Proteins Associated With Development of Chronic Q Fever.
Schoffelen T; Ammerdorffer A; Hagenaars JC; Bleeker-Rovers CP; Wegdam-Blans MC; Wever PC; Joosten LA; van der Meer JW; Sprong T; Netea MG; van Deuren M; van de Vosse E
J Infect Dis; 2015 Sep; 212(5):818-29. PubMed ID: 25722298
[TBL] [Abstract][Full Text] [Related]
19. Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients.
Sellner L; Heiss C; Benner A; Raab MS; Hillengass J; Hose D; Lehners N; Egerer G; Ho AD; Goldschmidt H; Neben K
Cancer; 2013 Jul; 119(13):2438-46. PubMed ID: 23576287
[TBL] [Abstract][Full Text] [Related]
20. The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors.
Horng T; Barton GM; Flavell RA; Medzhitov R
Nature; 2002 Nov; 420(6913):329-33. PubMed ID: 12447442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
